This trial is designed to study the safety and effectiveness of immunotherapy-based treatment combinations in patients with gastric or esophageal cancer.
3 Primary · 13 Secondary · Reporting Duration: From randomization up to death from any cause (up to approximately 3-6 years)
Active Control
Experimental Treatment
410 Total Participants · 12 Treatment Groups
Primary Treatment: Atezolizumab · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: